Welcome to our dedicated page for Kalaris Therapeutics SEC filings (Ticker: KLRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kalaris Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kalaris Therapeutics's regulatory disclosures and financial reporting.
Kalaris Therapeutics, Inc. (ticker KLRS) has filed Definitive Additional Proxy Materials (Form DEFA14A) ahead of its virtual Annual Meeting of Stockholders scheduled for August 12, 2025 at 11:30 a.m. ET. The notice outlines two routine proposals:
- Proposal 1: Elect Class II directors Srinivas Akkaraju, M.D., Ph.D. and Andrew Oxtoby to three-year terms expiring at the 2028 meeting.
- Proposal 2: Ratify Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
The Board recommends shareholders vote FOR each director nominee and FOR auditor ratification. Shareholders of record at the close of business on June 25, 2025 are entitled to vote. Materials are available at www.proxydocs.com/KLRS; holders must use their 12-digit control number to access voting tools. Paper or email copies of the proxy may be requested without charge until August 1, 2025. No other substantive matters, financial results, or transactional items are disclosed in this filing.
On 30 June 2025, GSK plc (GSK) repurchased 483,834 ordinary shares (nominal value 31¼ p) through its broker Merrill Lynch International under the non-discretionary buyback agreement announced on 4 June 2025.
• Price range: 1,385.50p – 1,405.00p
• Volume-weighted average price: 1,397.42p
• Cash outlay: ≈ £6.8 million
Since the start of the programme (4 June 2025) the company has reacquired 8,038,188 shares. Following the latest trade GSK holds 226,172,571 shares in treasury, leaving 4,089,197,628 shares outstanding (treasury stock equals 5.53 % of voting rights).
The transaction reduces the free float by roughly 0.012 %; while financially immaterial, it signals continuing capital-return discipline and fulfils UK Disclosure Guidance & Transparency Rule obligations. Detailed venue- and trade-level data accompany the filing for regulatory transparency.
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has filed a Form 8-K to announce scheduling details for its 2025 Annual Meeting of Stockholders.
The Board of Directors set August 12, 2025 as the meeting date. Because this date is more than 30 days later than the 2024 meeting anniversary, the company has adjusted deadlines for shareholder engagement:
- Rule 14a-8 proposals: Must be received by the Corporate Secretary no later than June 30, 2025 to be considered for inclusion in the proxy statement.
- Director nominations or other business under the company’s By-laws: Notice must also be delivered by June 30, 2025, in line with Section 2(a)(2) of the By-laws, because the meeting date is delayed by more than 60 days from the prior-year anniversary.
The filing contains no financial results, strategic transactions, or operational updates. Further details—such as the exact time, physical or virtual location, and the matters up for vote—will be provided in the forthcoming proxy statement.
The disclosure is routine, ensuring regulatory compliance and giving shareholders clear deadlines to submit proposals or nominations.
FAQ
What is the current stock price of Kalaris Therapeutics (KLRS)?
What is the market cap of Kalaris Therapeutics (KLRS)?
